June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
November 2010 in “Value in Health” Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
Dupilumab may cause hair loss, so patients should be monitored.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
14 citations
,
January 2017 in “Dermatology Online Journal” Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
25 citations
,
May 2019 in “Biologics” Dupilumab can cause rare side effects like a rash on the face and neck.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
9 citations
,
April 2024 in “Advanced Drug Delivery Reviews” High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
1 citations
,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
July 2024 in “Reactions Weekly”
33 citations
,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
February 2010 in “Journal of The American Academy of Dermatology” Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
1 citations
,
July 2015 in “British Journal of Dermatology” Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
May 2005 in “Molecular Carcinogenesis” mrp/plf-mRNA can indicate tumor-promoting effects in skin.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.